TRDA

+ Watchlist + Portfolio

Entrada Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.78
52-Week Range: $5.02 – $16.45
Market Cap: $295.92M
P/E (TTM): —
EPS (TTM): -3.96
Dividend Yield: —

Advanced Metrics

Price/Book: 1.01
PEG Ratio: —
Return on Equity: -54.10%
Return on Assets: -29.20%
Gross Margin: 0.00%
Operating Margin: -5007.02%
Profit Margin: 0.00%
Current Ratio: 10.89
Debt/Equity: 0.21
Total Debt: $48.54M
Free Cash Flow: $-77.67M
Revenue Growth: -53.90%
Earnings Growth: —
Enterprise Value: $106.06M

TRDA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$129.01M	$210.78M	$25.42M
Research & Development	$66.61M	$99.88M	$125.31M	$142.27M
Selling, General & Admin	$30.64M	$32.29M	$38.47M	$41.05M
Operating Expenses	$97.25M	$132.18M	$163.77M	$183.32M
Operating Income	-$97.25M	-$3.16M	$47.01M	-$157.90M
EBITDA	-$95.35M	-$321.00K	$50.78M	-$153.80M
Pretax Income	-$94.62M	$12.06M	$66.48M	-$142.83M
Income Tax	$0.00	$18.74M	$859.00K	$924.00K
Net Income	-$94.62M	-$6.68M	$65.63M	-$143.75M
Diluted EPS	-3.02	-0.20	1.68	-3.47
Diluted Shares	31.29M	33.05M	39.00M	41.37M

TRDA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$45.16M	$67.60M	$101.21M	$90.39M
Receivables	$0.00	$5.88M	$3.68M	$1.18M
Current Assets	$209.88M	$369.77M	$440.04M	$306.25M
Total Assets	$252.06M	$469.19M	$526.32M	$377.38M
Current Liabilities	$21.97M	$158.80M	$39.48M	$24.45M
Total Debt	$25.94M	$68.23M	$59.21M	$50.93M
Total Liabilities	$39.50M	$226.83M	$97.64M	$71.25M
Retained Earnings	-$188.28M	-$194.97M	-$129.34M	-$273.09M
Shareholders' Equity	$212.55M	$242.36M	$428.68M	$306.13M
Working Capital	$187.90M	$210.97M	$400.56M	$281.80M

TRDA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$93.79M	$139.80M	-$41.56M	-$128.51M
Capital Expenditure	-$2.89M	-$5.61M	-$3.16M	-$1.04M
Free Cash Flow	-$96.67M	$134.19M	-$44.72M	-$129.55M
Depreciation & Amortisation	$1.90M	$2.84M	$3.77M	$4.10M
Stock-Based Compensation	$9.89M	$13.11M	$17.91M	$19.61M
Investing Cash Flow	-$148.65M	-$138.40M	-$27.80M	$116.81M
Financing Cash Flow	$479.00K	$21.04M	$102.96M	$887.00K
Net Change in Cash	-$241.96M	$22.45M	$33.61M	-$10.82M

TRDA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$20.56M	$1.95M	$1.61M	$1.30M	$875.00K
Research & Development	$32.07M	$37.88M	$38.36M	$33.96M	$33.05M
Selling, General & Admin	$10.27M	$10.92M	$10.30M	$9.55M	$10.12M
Operating Expenses	$42.35M	$48.80M	$48.66M	$43.51M	$43.18M
Operating Income	-$21.79M	-$46.85M	-$47.05M	-$42.21M	-$42.30M
EBITDA	-$20.84M	-$45.81M	-$45.82M	-$41.32M	-$41.50M
Pretax Income	-$17.35M	-$42.92M	-$43.48M	-$39.07M	-$39.68M
Income Tax	$0.00	$178.00K	$654.00K	$92.00K	$38.00K
Net Income	-$17.35M	-$43.10M	-$44.13M	-$39.16M	-$39.72M
Diluted EPS	-0.42	-1.04	-1.06	-0.94	-0.95
Diluted Shares	41.07M	41.34M	41.46M	41.60M	41.84M

TRDA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$67.84M	$72.48M	$93.29M	$90.39M	$76.44M
Receivables	$2.04M	$1.18M	$1.20M	$1.18M	—
Current Assets	$403.19M	$369.15M	$338.26M	$306.25M	$266.87M
Total Assets	$486.48M	$448.78M	$412.90M	$377.38M	$335.52M
Current Liabilities	$18.43M	$19.80M	$24.02M	$24.45M	$19.20M
Total Debt	$57.00M	$54.74M	$52.40M	$50.93M	$49.75M
Total Liabilities	$69.22M	$69.28M	$72.18M	$71.25M	$64.66M
Retained Earnings	-$146.69M	-$189.80M	-$233.93M	-$273.09M	-$312.81M
Shareholders' Equity	$417.26M	$379.50M	$340.72M	$306.13M	$270.60M
Working Capital	$384.76M	$349.34M	$314.24M	$281.80M	$247.68M

TRDA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$38.51M	-$29.49M	-$28.31M	-$32.20M	-$41.70M
Capital Expenditure	-$1.14M	-$275.00K	—	—	-$44.00K
Free Cash Flow	-$39.65M	-$29.76M	-$28.14M	-$32.00M	-$41.74M
Depreciation & Amortisation	$946.00K	$1.03M	$1.23M	$886.00K	$805.00K
Stock-Based Compensation	$5.09M	$5.05M	$5.12M	$4.36M	$4.74M
Investing Cash Flow	$4.78M	$33.80M	$49.11M	$29.12M	$26.99M
Financing Cash Flow	$350.00K	$337.00K	$8.00K	$192.00K	$100.00K
Net Change in Cash	-$33.37M	$4.64M	$20.80M	-$2.89M	-$14.61M

Market Snapshot

About

Entrada Therapeutics is a clinical-stage biotechnology company developing intracellular therapeutics using its Endosomal Escape Vehicle (EEV) platform. The company focuses on treating diseases by enabling the delivery of therapeutic molecules into cells, targeting oncology and neuromuscular disorders. Entrada is advancing multiple programs through clinical trials to address significant unmet medical needs.